/**/ document.writeln("\n\n\n\n\n \n\n\n\n\n \n \n \n\n
\n\n \n
\n \n \n \n \n
 Recent News for Nymox Pharmaceutical Corp.\n \n\n\n\n\n
Nov 22 9:11 PM EST
\n\n\n\n
\n \n
\n \n \n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n
\n\n Nov 13, 2009 9:44 AM EST
\n\n \n Nymox Reports Third Quarter 2009 Financial Results - GlobeNewswire\n \n \n
\n\n Oct 14, 2009 11:23 AM EDT
\n\n \n Nymox's NX-1207 to be Clinically Tested for Prostate Cancer - GlobeNewswire\n \n \n
\n\n Oct 05, 2009 12:20 PM EDT
\n\n \n Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207 Treatment for BPH - GlobeNewswire\n \n \n
\n\n Aug 27, 2009 10:00 AM EDT
\n\n \n ParagonReport.com Complimentary Analyst Research for General Electric Co. (NYSE: GE), E*TRADE Financial Corporation (NASDAQ: ETFC), Nymox Pharmaceutical Corporation (NASDAQ: NYMX) and DR Horton Inc. (NYSE: DHI) - Marketwire\n \n \n
\n\n Aug 26, 2009 10:05 AM EDT
\n\n \n Nymox's NX-1207 Shows Major Effect On Liver Cancer - GlobeNewswire\n \n \n
\n\n Aug 14, 2009 9:23 AM EDT
\n\n \n Nymox Reports Second Quarter 2009 Financial Results - GlobeNewswire\n \n \n
\n\n Jun 02, 2009 12:46 PM EDT
\n\n \n Nymox Announces Dosing of First Patient in Phase 3 Trial for NX-1207 for BPH - GlobeNewswire\n \n \n
\n
\n\n");